Posts by David Etchison
Photo Gallery: 2023 Legislative Reception
Approximately 300 NCBIO member representatives and North Carolina law makers came together Wednesday, March 1, at the NCBIO Legislative Reception held at the NC Museum of History in Raleigh.
Read MoreCollaboration and statewide support make North Carolina a thriving hub of urgently needed innovation in rare disease.
The rarest day on the calendar is the one that does not even occur in every year: February 29. In 2008, this was designated as Rare Disease Day and since then, the last day of February has been an opportunity to draw attention to, honor and support people living with these conditions.
Read MoreNCBIO reaches quarter-million-dollar goal for life sciences scholarships
With a significant gift from Amgen, NCBIO has reached its goal of raising $250,000 to create a scholarship fund at the NC Community College Foundation for students pursuing degrees and certifications in the life sciences. The total amount of gifts and pledges now stands at approximately $260,000.
Read MoreQ&A with the NCBIO Clinical Research Forum panel explores clinical trial barriers
An expert panel explored the current state of clinical trial participation at the NCBIO Clinical Research Forum held Tuesday, Nov. 29. Panelists talked about ways to lower the barriers that stop patients from participating in clinical trials and discussed strategies for achieving diversity. They also explored the role of patient advocates and gave special consideration to efforts focused on rare diseases.
Read More2022 Annual Meeting discusses workforce, health equity, investment, locating in NC
The 2022 NCBIO Annual Meeting held Oct. 12 at the NC Biotechnology Center featured expert panels on locating in North Carolina, talent recruitment, financial trends and health equity and disparities. The meeting returned to being fully in person this year after several years of being virtual or offering an online option due to the COVID pandemic.
Read MoreWhere things stand with the TRIPS waiver
The World Trade Organization is considering continuing to waive certain intellectual property rights on COVID-19 diagnostics and therapeutics, following a recent decision to do the same for vaccines.
Read MoreExpanding COVID IP waiver would harm small, medium enterprises, CSBA says
Every member of the Council of State Bioscience Associations signed a letter to President Joe Biden expressing serious concerns with the proposed expansion of IP protections for COVID technology.
Read More2022 NCBIO Year in Review
In this past year, we emerged from the isolation of COVID-19 thanks in no small part to the heroic work of the life sciences industry in developing vaccines, rapid tests and new treatments that have made the pandemic much more manageable. In spite of this success, we have faced tremendous pressure at the federal level with threats to intellectual property, the lifeblood of the industry, and a push to insert price controls with potential repercussions on innovation.
Read MoreBurr shares insights from 28-year Congressional career
Sen. Richard Burr reflected on his 28-year career in Congress and discussed FDA reform, the nation’s response to future pandemics and the pitfalls of the nation’s regulatory system at the 2022 NCBIO Annual Dinner held Monday, Oct. 10, at the NC Biotechnology Center.
Read MoreWorkforce and talent development topics of discussion at September BMF meeting
At their quarterly meeting held Wednesday, Sept. 14, members of the NCBIO Biomanufacturers Forum learned about efforts and options for bolstering workforce and talent development in North Carolina. Members also received an update on the $25 million Build Back Better awarded to expand, connect and promote training and career opportunities in North Carolina.
Read More